استمتع بـUnlimited مع Magzter GOLD

استمتع بـUnlimited مع Magzter GOLD

احصل على وصول غير محدود إلى أكثر من 9000 مجلة وصحيفة وقصة مميزة مقابل

$149.99
 
$74.99/سنة

يحاول ذهب - حر

Upskilling and flexibility are key to staying relevant as hiring grows

BioSpectrum Asia June 2025

|

BioSpectrum Asia

With ongoing uncertainty, geopolitical tensions, and recession risks, the life sciences job market remains volatile. The year 2024 saw continued layoffs, cautious investor sentiment, and growing competition for fewer job openings. As biopharma companies restructure, hiring patterns are changing, especially at mid and senior levels. What are the current trends, and which sectors are hiring the most? Let's find out.

- Ayesha Siddiqui

The biopharma job market has been tough, with widespread downsizing and frequent layoffs across big pharma. But the worst may be over. Hiring activity is picking up, especially in the Asia-Pacific (APAC) region. A quick search on our sister website, BioSpectrum jobs for April and May 2025 shows strong, diverse recruitment across all levels from internships to senior leadership in key hubs like Singapore, Tokyo, Bengaluru, and Shanghai. Demand is high for clinical research, regulatory affairs, medical science liaison, and digital marketing roles, while leadership hiring focuses on strategy, sales, and commercial functions.

“The pharmaceutical sector's job landscape has showcased an improving trend in recent months. For instance, job postings were up by around 8 per cent in April 2025 compared to the previous month. Similarly, March 2025 also saw job postings register a month-on-month growth of more than 25 per cent,” said Sherla Sriprada, Senior Business Fundamentals Analyst at GlobalData.

This sustained uptick in hiring reflects how companies are responding to evolving workforce dynamics and talent demands.

“The biopharma job market is experiencing several key trends. High executive turnover, as observed in 2024, continues to influence recruitment needs. Companies are leveraging headquarters and regional resources to supplement local talent with global expertise. They are also focusing on candidates who can learn and grow in dynamic environments, due to cautious attitudes toward job changes and the emergence of younger generations,” said Terrence Chen, Manager, Robert Walters China.

Sherla mentions that there have been notable job postings for roles related to clinical trials, regulatory compliance, immuno-oncology, cell & gene therapy, and digital therapeutics. Meanwhile, there is also demand for senior positions and the skills sought for these roles typically include:

  • Leadership experience

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size